Breaking News Instant updates and real-time market news.

PSDV

pSivida

$2.94

-0.07 (-2.33%)

07:09
10/04/16
10/04
07:09
10/04/16
07:09

pSivida Phase 3 trial of Medidur meets enrollment target

pSivida announced that its second Phase 3 trial of Medidur in chronic, non-infectious posterior segment uveitis met its target enrollment of 150 patients. The trial is being conducted in clinical sites in India, with the same study design and endpoints as the first Phase 3 trial conducted in the U.S., EU and India. The results of both Phase 3 trials will support U.S. product registration, with NDA submission planned for the second half of 2017. Filing for EU registration remains on track for Q1 of 2017. This first Medidur trial met the primary efficacy endpoint of prevention of recurrence of posterior segment uveitis at six months in December 2015. Primary efficacy endpoint readout in the second study is expected in the second half of 2017.

PSDV pSivida
$2.94

-0.07 (-2.33%)

12/17/15
NORL
12/17/15
NO CHANGE
Target $10
NORL
Outperform
Alimera sale would have implications for pSivida, says Northland
Northland analyst Suraj Kalia noted the Reuters report that Alimera Sciences (ALIM), a licensee of pSivida (PSDV), is exploring strategic alternatives. If Alimera get bought, the acquirer could keep its current contractual arrangement with pSivida, under which it is entitled to 20% of "net profits" on sales of Iluvien in DME, in place, or could try to negotiate an upfront lump sum payment to pSivida for Iluvien, the analyst stated. Kalia keeps an Outperform rating and $10 price target on pSivida shares.
12/22/15
NORL
12/22/15
NO CHANGE
Target $10
NORL
Outperform
pSivida' Meddidur results a big positive, says Northland
Northland analyst Suraj Kalia said pSivida announced strong Phase III results from its Medidur uveitis study. Overall, the data improves pSivida's bargaining position if a strategic buyer steps in for partner Alimera, and it positions pSivida strongly from a go-direct strategy perspective, the analyst reported. Kalia rates pSivida an Outperform with a $10 price target on shares.
12/23/15
LTCO
12/23/15
NO CHANGE
Target $12.5
LTCO
Buy
pSivida price target raised to $12.50 from $8 at Ladenburg
Ladenburg analyst Matthew Kaplan raised pSivida's price target to $12.50 from $8 and reiterated his Buy rating following the "outstanding" top-line data for first Medidur Phase 3 trial in treating chronic noninfectious posterior uveitis. Kaplan said the data presents a strong case that the FDA may allow Medidur NDA filing without completion of the 2nd Phase 3 study.
06/23/16
FBRC
06/23/16
NO CHANGE
FBRC
Outperform
pSivida could see positive catalysts shortly, says FBR Capital
FBR Capital analyst Vernon Bernardino thinks pSivida is on track to announce the 12-month data from the first Medidur Phase III trial, which he expects to be a significant catalyst, in July and that an IND filing for a Durasert osteoarthritis product by the company's partner is on track to be announced in the next few weeks. Given the company's upcoming catalysts, its potential to turn positive on cash flow in the near-term and its attractive potential as an acquisition target, the firm reiterates its Outperform rating on pSivida.

TODAY'S FREE FLY STORIES

TLRD

Tailored Brands

$26.39

7.4597 (39.41%)

13:02
12/08/16
12/08
13:02
12/08/16
13:02
Hot Stocks
Tailored Brands surges as Jos. A. Bank turnaround gains traction »

Shares of Tailored Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

GE

General Electric

$31.68

0.08 (0.25%)

13:01
12/08/16
12/08
13:01
12/08/16
13:01
Hot Stocks
GE Transportation acquires Iders Incorporated, terms not disclosed »

GE Transportation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

ESRX

Express Scripts

$75.85

-0.88 (-1.15%)

13:01
12/08/16
12/08
13:01
12/08/16
13:01
Periodicals
Citron cautious on Express Scripts, has $45 target on shares »

Citron Research tweeted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSY

Insys Therapeutics

$10.70

-0.54 (-4.80%)

12:57
12/08/16
12/08
12:57
12/08/16
12:57
Hot Stocks
Justice Department arrests former Insys executives, including CEO »

The U.S. Attorney's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBOT

Microbot Medical

$7.75

-0.3 (-3.73%)

12:56
12/08/16
12/08
12:56
12/08/16
12:56
Hot Stocks
Breaking Hot Stocks news story on Microbot Medical »

Greenblock Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$19.39

-0.82 (-4.06%)

12:53
12/08/16
12/08
12:53
12/08/16
12:53
Recommendations
Horizon Pharma analyst commentary  »

BMO cuts Horizon Pharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 08

    Dec

  • 14

    Dec

MLSS

Milestone Scientific

$1.77

-0.3254 (-15.50%)

12:51
12/08/16
12/08
12:51
12/08/16
12:51
Hot Stocks
Milestone Scientific: Henry Schein ahead of schedule in The Wand training »

Milestone Scientific…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTI

Universal Technical

$3.62

0.37 (11.38%)

12:44
12/08/16
12/08
12:44
12/08/16
12:44
Hot Stocks
Breaking Hot Stocks news story on Universal Technical »

Universal Technical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FEYE

FireEye

$13.61

0.41 (3.11%)

12:40
12/08/16
12/08
12:40
12/08/16
12:40
Options
FireEye calls active »

FireEye calls active. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

12:40
12/08/16
12/08
12:40
12/08/16
12:40
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

UTI

Universal Technical

$3.62

0.37 (11.38%)

12:38
12/08/16
12/08
12:38
12/08/16
12:38
Hot Stocks
Breaking Hot Stocks news story on Universal Technical »

Universal Technical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTI

Universal Technical

$3.62

0.37 (11.38%)

12:38
12/08/16
12/08
12:38
12/08/16
12:38
Hot Stocks
Breaking Hot Stocks news story on Universal Technical »

Universal Technical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNST

Monster Beverage

$44.47

0.1 (0.23%)

12:35
12/08/16
12/08
12:35
12/08/16
12:35
Options
Monster Beverage put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PF

Pinnacle Foods

$51.04

0.58 (1.15%)

12:31
12/08/16
12/08
12:31
12/08/16
12:31
Conference/Events
Pinnacle Foods to hold an investor luncheon »

Investor Luncheon where…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTI

Universal Technical

$3.62

0.37 (11.38%)

12:30
12/08/16
12/08
12:30
12/08/16
12:30
Hot Stocks
Universal Technical: No pending non-public disclosures to account for stock rise »

Universal Technical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:30
12/08/16
12/08
12:30
12/08/16
12:30
General news
U.S. Household net worth rose »

U.S. Household net worth…

SAN

Banco Santander

$5.19

0.1549 (3.07%)

12:25
12/08/16
12/08
12:25
12/08/16
12:25
Options
Banco Santander call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
12/08/16
12/08
12:25
12/08/16
12:25
Conference/Events
Wells Fargo economists hold an analyst/industry conference call »

Chief Economist Silvia,…

TWTR

Twitter

$19.34

-0.14 (-0.72%)

12:21
12/08/16
12/08
12:21
12/08/16
12:21
Periodicals
Spotify cancels talks to acquire SoundCloud, TechCrunch says »

Spotify has pulled out of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIXG

Aixtron

$4.15

0.042 (1.02%)

12:17
12/08/16
12/08
12:17
12/08/16
12:17
Hot Stocks
Fujian Grand Chip cancels Aixtron takeover bid after U.S. intervention »

Grand Chip Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
12/08/16
12/08
12:16
12/08/16
12:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:16
12/08/16
12/08
12:16
12/08/16
12:16
Technical Analysis
NASDAQ market internals summary »

Volume is lighter for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNC

PNC Financial

$114.46

1.79 (1.59%)

12:15
12/08/16
12/08
12:15
12/08/16
12:15
Options
PNC Financial put volume heavy and directionally bearish »

Bearish flow noted in PNC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jan

GOOG

Alphabet

$771.19

12.08 (1.59%)

, GOOGL

Alphabet Class A

$791.47

15.29 (1.97%)

12:12
12/08/16
12/08
12:12
12/08/16
12:12
Hot Stocks
Google enters partnership with Gupshup for Actions on Google Assistant »

Gupshup announced a…

GOOG

Alphabet

$771.19

12.08 (1.59%)

GOOGL

Alphabet Class A

$791.47

15.29 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

12:10
12/08/16
12/08
12:10
12/08/16
12:10
General news
U.S. VIX equity volatility is up another 2% to the 12.40 area »

U.S. VIX equity…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.